2022
Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization
Adam LC, Savic LJ, Chapiro J, Letzen B, Lin M, Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging 2022, 89: 112-119. PMID: 35777239, PMCID: PMC9470015, DOI: 10.1016/j.clinimag.2022.06.013.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionHepatic metastasesResponse assessment methodsPartial responseTransarterial chemoembolizationResponse assessmentTumor primaryStratification of responseRare primary tumorResponse Evaluation CriteriaRetrospective bicentric studyAssessment of responseQuantitative European AssociationLiver metastasesMajor complicationsBicentric studyPrimary tumorRare tumorEarly surrogateTreatment responseCT scanPatientsRECISTSolid tumors
2021
Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinoma
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases
2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model
Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European Radiology 2017, 27: 4995-5005. PMID: 28677067, PMCID: PMC5675796, DOI: 10.1007/s00330-017-4856-2.Peer-Reviewed Original ResearchConceptsMultivariate Cox proportional hazards modelConventional transarterial chemoembolisationMedian overall survivalPropensity score analysisHepatic progression-free survivalDrug-eluting beads TACEYttrium-90 radioembolisationProgression-free survivalDEB-TACELiver metastasesOverall survivalBeads TACENeuroendocrine tumor liver metastasesWorld Health Organization criteriaCox proportional hazards modelIntra-arterial therapyMethodsThis retrospective analysisResponse Evaluation CriteriaScore analysisSignificant survival benefitLonger overall survivalGastroenteropancreatic neuroendocrine tumorsLog-rank testEntire study populationProportional hazards model
2016
Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology 2016, 283: 160838. PMID: 27831830, PMCID: PMC5425309, DOI: 10.1148/radiol.2016160838.Peer-Reviewed Original ResearchConceptsNeuroendocrine liver metastasesWorld Health OrganizationContrast material-enhanced magnetic resonance (MR) imagesFirst TACE procedureResponse Evaluation CriteriaKaplan-Meier curvesTreatment response biomarkersTransarterial chemoembolization proceduresInstitutional review boardFirst TACELiver methodLiver metastasesIndependent predictorsTumor burdenRetrospective studyTACE proceduresCox regressionOnly biomarkerSurvival differencesChemoembolization proceduresTreatment responseResponse biomarkersPatientsSolid tumorsNormal liverRenal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Translational Oncology 2016, 9: 377-383. PMID: 27641641, PMCID: PMC5021812, DOI: 10.1016/j.tranon.2016.07.005.Peer-Reviewed Original ResearchRenal cell carcinomaOverall survivalIntraarterial therapyMagnetic resonance imagingTumor responseTumor volumeMetastatic renal cell carcinomaRenal cell carcinoma metastaticCox proportional hazards modelEarly response assessmentMedian overall survivalResponse Evaluation CriteriaKaplan-Meier curvesLog-rank testCourse of diseaseProportional hazards modelQuantitative European AssociationOnly significant predictorWorld Health OrganizationRCC metastaticCarcinoma metastaticLiver metastasesCell carcinomaSurrogate markerTreatment response
2015
Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. CardioVascular And Interventional Radiology 2015, 38: 1548-1556. PMID: 26001366, PMCID: PMC4651808, DOI: 10.1007/s00270-015-1129-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyContrast MediaEthiodized OilFemaleFollow-Up StudiesHumansImage EnhancementImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsLipiodol depositionConventional transarterial chemoembolizationTumor responseOverall tumor volumeTumor volumeCE-MRIHepatocellular carcinomaTransarterial chemoembolizationTumor necrosisContrast-enhanced magnetic resonance imagingNecrotic tumour volumeResponse Evaluation CriteriaT-testMagnetic resonance imagingStudent's t-testMethodsThis IRBTarget lesionsRetrospective analysisSolid tumorsResonance imagingSpearman rank-order correlationPatientsCone-beam CTCBCTChemoembolization
2014
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers
Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers. Radiology 2014, 275: 438-47. PMID: 25531387, PMCID: PMC4409467, DOI: 10.1148/radiol.14141180.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaTumor diameterHazard ratioTumor responseTumor volumeResponse rateCox proportional hazard ratiosStaging markersTumor response rateProportional hazard ratiosResponse Evaluation CriteriaSurvival of patientsKaplan-Meier analysisSingle-institution analysisBaseline magnetic resonance imagesHigh response rateInstitutional review boardOverall survivalLiver (EASL) guidelinesPatient cohortImaging markerRadiologic measurementsLarge lesionsAssessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI
Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Review Of Anticancer Therapy 2014, 15: 199-205. PMID: 25371052, PMCID: PMC4304995, DOI: 10.1586/14737140.2015.978861.Peer-Reviewed Original ResearchConceptsTumor responseResponse Evaluation CriteriaTumor response criteriaMajor clinical interestLiver cancer therapyLiver cancer lesionsClinical evidenceIntraarterial therapyCancer lesionsSolid tumorsResponse criteriaAnatomic methodsClinical interestImaging modalitiesCancer therapyTumor analysisTherapyMRILesionsTumorsUveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization
Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic LJ, Tacher V, Kamel IR, Geschwind JF. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology 2014, 7: 447-455. PMID: 24953419, PMCID: PMC4202794, DOI: 10.1016/j.tranon.2014.05.004.Peer-Reviewed Original ResearchFirst transarterial chemoembolizationEarly tumor responseTransarterial chemoembolizationWorld Health OrganizationOverall survivalTumor responseTarget lesionsTumor volumeTumor enhancementUveal melanomaContrast-enhanced magnetic resonance imagingNon-target lesionsUveal melanoma metastaticMedian overall survivalResponse Evaluation CriteriaKaplan-Meier methodLog-rank testMetastatic uveal melanomaMagnetic resonance imagingMelanoma metastaticSurrogate biomarkerSolid tumorsResonance imagingResponse criteriaLesions